🎁 Black Friday: up to 50% off of annual plans
Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
0.7113
-0.0371 (-4.96%)
At close: Nov 20, 2026, 4:00 PM EST
0.7300
+0.0187 (2.63%)
After-hours: Nov 20, 2026, 7:53 PM EST

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.

The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease.

It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia.

Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Annovis Bio, Inc.
Annovis Bio logo
CountryUnited States
Founded2008
IPO DateJan 29, 2020
IndustryBiotechnology
SectorHealthcare
Employees7
CEOMaria Maccecchini

Contact Details

Address:
101 Lindenwood Drive, Suite 225
Malvern, Pennsylvania 19355
United States
Phone484 875 3192
Websiteannovisbio.com

Stock Details

Ticker SymbolANVS
ExchangeNYSE
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code1477845
CUSIP Number03615A108
ISIN NumberUS03615A1088
Employer ID26-2540421
SIC Code2834

Key Executives

NamePosition
Dr. Maria L. Maccecchini Ph.D.Founder, Acting Chief Financial Officer, Chief Executive Officer, President and Executive Director
Dr. Cheng Fang Ph.D.Chief Scientific Officer
Eve M. Damiano M.S., RACSenior Vice President of Regulatory Operations
Blake Jensen M.B.A.Head of Quality
Hilda MaibachSenior Vice President of Statistics

Latest SEC Filings

DateTypeTitle
Nov 13, 202610-QQuarterly Report
Nov 13, 20268-KCurrent Report
Nov 5, 20268-KCurrent Report
Nov 5, 2026424B5Filing
Nov 4, 2026424B5Filing
Nov 4, 20268-KCurrent Report
Nov 4, 20268-KCurrent Report
Oct 30, 20268-KCurrent Report
Oct 20, 20268-KCurrent Report
Oct 15, 2026SCHEDULE 13G/AFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides